Stockscreener 앱 받기
7.87
4.02%
-0.33
전일 마감가:
$8.20
열려 있는:
$8.13
하루 거래량:
45,442
Relative Volume:
0.97
시가총액:
$18.40M
수익:
-
순이익/손실:
$-4.85M
주가수익비율:
-25.39
EPS:
-0.31
순현금흐름:
$-3.95M
1주 성능:
-3.67%
1개월 성능:
-4.61%
6개월 성능:
-29.54%
1년 성능:
-56.76%
1일 변동 폭
$7.86
$8.2944
1주일 범위
$7.86
$8.7899
52주 변동 폭
$6.42
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
명칭
Cadrenal Therapeutics Inc
전화
904-300-0701
주소
822 A1A NORTH, PONTE VEDRA
CVKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
7.87 | 19.17M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-18 | 개시 | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
(CVKD) Risk Channels and Responsive Allocation - Stock Traders Daily
CVKD: VLX-1005 and Tecarfarin lead a strategy to address unmet needs in rare anticoagulation markets - TradingView — Track All Markets
Trend Report: Can GMGI stock double in the next yearJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - baoquankhu1.vn
Income Plays: Is Cadrenal Therapeutics Incs ROIC above industry averageEarnings Miss & Fast Moving Stock Watchlists - baoquankhu1.vn
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder By Investing.com - Investing.com Nigeria
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder - Investing.com
New drug aims to cut dangerous blood clots from a rare reaction to heparin - Stock Titan
Cadrenal Therapeutics, Inc. - MSN
Will Cadrenal Therapeutics Inc. stock keep outperforming rivals2025 Key Highlights & Community Verified Watchlist Alerts - Улправда
Will Cadrenal Therapeutics Inc. stock benefit from commodity pricesWeekly Trend Summary & Real-Time Volume Trigger Notifications - Улправда
Can Cadrenal Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Weekly Consistent Profit Watchlists - Улправда
What sentiment indicators say about Cadrenal Therapeutics Inc. stockMarket Growth Report & Weekly Market Pulse Updates - Улправда
Risk Analysis: Why Cadrenal Therapeutics Inc. stock remains undervaluedBreakout Watch & Daily Profit Maximizing Tips - Улправда
How Cadrenal Therapeutics Inc. stock trades during market volatilityJuly 2025 Institutional & Stepwise Trade Execution Plans - Улправда
Is Cadrenal Therapeutics Inc. stock a contrarian buyTrade Performance Summary & Step-by-Step Swing Trade Plans - Улправда
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
(CVKD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock - Defense World
Cadrenal Therapeutics Earnings Notes - Trefis
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - The Globe and Mail
How a small biotech is building an emergency anticoagulation plan - Stock Titan
Cadrenal Therapeutics announces new securities purchase agreement - MSN
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - ACCESS Newswire
Inside the drug startup rebuilding blood thinners for medicine’s toughest cases - Stock Titan
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - The Globe and Mail
Cadrenal Therapeutics Appoints Dr. Golden to Board - MSN
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis - Defense World
Downgrade Watch: Will Cadrenal Therapeutics Inc stock benefit from commodity pricesEarnings Beat & Detailed Earnings Play Alerts - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru
How Cadrenal Therapeutics Inc. stock performs in stagflation2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Is Cadrenal Therapeutics Inc. stock recession proofWeekly Profit Recap & Capital Efficient Trading Techniques - Улправда
Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Buying & Community Verified Trade Signals - Улправда
Can Cadrenal Therapeutics Inc. stock resist market sell offsJuly 2025 Movers & Technical Buy Zone Confirmations - Улправда
Can Cadrenal Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Summary & Daily Entry Point Trade Alerts - Улправда
Aug PreEarnings: Is Cadrenal Therapeutics Inc. stock a contrarian buy2025 Market Sentiment & Weekly High Momentum Picks - DonanımHaber
Ideas Watch: Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Selling & Weekly Setup with ROI Potential - Улправда
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - Улправда
How Cadrenal Therapeutics Inc. stock responds to policy changes2025 Bull vs Bear & Expert Curated Trade Setups - Улправда
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Volume & Technical Pattern Based Signals - Улправда
Cadrenal Therapeutics to conduct partnering and investor meetings - marketscreener.com
Cadrenal Therapeutics To Conduct Partnering And Investor Meetings - TradingView — Track All Markets
Cadrenal Therapeutics, Inc. Management to Hold Investor and Partner Meetings at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - Sahm
Cadrenal Therapeutics to Conduct Partnering and Investor - GlobeNewswire
Cadrenal Therapeutics Announces New Securities Purchase Agreement - TipRanks
Understanding the Setup: (CVKD) and Scalable Risk - Stock Traders Daily
CVKDCadrenal Therape Latest Stock News & Market Updates - Stock Titan
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - guardonline.com
Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan
Cadrenal Therapeutics Inc (CVKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):